Commercializing Cell and Gene Therapies: Overcoming the Barriers to Commercial Success

Home / Intelligence / White Papers / Commercializing Cell and Gene Therapies: Overcoming the Barriers to Commercial Success

Cell and Gene Therapy (CGT) is an exciting new frontier in the biopharmaceutical industry. The novelty of the technology and market introduces many complexities for companies commercializing CGTs.

This white paper analyzes the challenges faced and outlines six key questions to consider for reducing complexity and supporting commercial success:

  1. Are we confident in the supply chain right up until administration of the treatment to the patient?
  2. Do we have the right pricing, reimbursement, and evidence model in place, not just the right price?
  3. Can we trace our product journey and understand every stakeholder that is involved in the delivery of our treatment?
  4. Do we have a field force that can manage the unique task of preparing the market and marketing the CGT treatment?
  5. Have we set the right expectations for the uptake of our CGT with our stakeholders?
  6. Have we identified how to build a platform that supports longer-term competitiveness in the CGT market?


Jackson Carroll, Dr. Tony Xu, Krista Perry, Christian Frois, Brenna Liponis, Alexander Fink

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email